BioNTech & Moderna

BioNTech: BioNTech is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

BioNTech: BioNTech, a competitor in mRNA vaccines, may be spurred by Moderna's approval to advance its own flu programs.

Moderna: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.

BioNTech: BioNTech is also developing mRNA cancer vaccines, and the trial success boosts confidence in the technology and its own programs.

Moderna: Moderna is the developer of the mRNA vaccine and the primary beneficiary, with its stock surging over 120% and market cap increasing by nearly $40 billion. The trial success validates its mRNA platform beyond COVID-19 and could lead to a new revenue stream.

BioNTech: BioNTech, in collaboration with Pfizer, halted a large U.S. trial for their updated COVID-19 vaccine due to low enrollment, potentially impacting future approvals and market share for the 50-64 age group.